Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22468530 | 0.83 | MAPK14 (0.51) | SMN1; SMN2KDM4ETSHRALDH1A1L3MBTL1 | |
| SCHEMBL13948889 | 0.82 | LIPE (0.36) | RAB9ACYP2C19NPC1 | |
| SCHEMBL22468524 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAKDM4ETSHRALDH1A1 | |
| SCHEMBL14077653 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2GAAKDM4ETSHRALDH1A1 | |
| SCHEMBL4740641 | 0.78 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAKDM4ETSHRALDH1A1 | |
| SCHEMBL2214493 | 0.77 | MAPK14 (0.40) | MAPK14KMT2ALCK | |
| SCHEMBL4225203 | 0.77 | SIRT2 (0.38) | MAPK14 | |
| SCHEMBL14077637 | 0.77 | HDAC1 (0.37) | — | |
| SCHEMBL4684166 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2GAAKDM4ETSHRALDH1A1 | |
| SCHEMBL14630700 | 0.77 | CA1 (0.53) | SMN1; SMN2GAAKDM4ETSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214623-A1 | N-(2,2-Dimethylpropyl)-6- -3-Pyridinecarboxamide | CHANDI AMRIK | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214623-A1 | N-(2,2-Dimethylpropyl)-6- -3-Pyridinecarboxamide | MAPKAPK2, MAP3K2, MAP4K2 | SMN1; SMN2 741/4885GAA 3239/4885KDM4E 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.